Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nephropathy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Nephropathy - Pipeline Review, H1 2015', provides an overview of the Nephropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nephropathy Overview 6 Therapeutics Development 7 Pipeline Products for Nephropathy - Overview 7 Pipeline Products for Nephropathy - Comparative Analysis 8 Nephropathy - Therapeutics under Development by Companies 9 Nephropathy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Nephropathy - Products under Development by Companies 13 Nephropathy - Companies Involved in Therapeutics Development 14 Anthera Pharmaceuticals� Inc. 14 Boehringer Ingelheim GmbH 15 ChemoCentryx, Inc. 16 Ischemix 17 Promedior, Inc. 18 Nephropathy - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 blisibimod - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CCX-168 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CMX-2043 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 imatinib mesylate - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PRM-151 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 R-801 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 R-901 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Nephropathy - Recent Pipeline Updates 44 Nephropathy - Dormant Projects 53 Nephropathy - Discontinued Products 54 Nephropathy - Product Development Milestones 55 Featured News & Press Releases 55 Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 55 Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod 55 Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 55 Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Nephropathy, H1 2015 7 Number of Products under Development for Nephropathy - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Nephropathy - Pipeline by Anthera Pharmaceuticals� Inc., H1 2015 14 Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2015 15 Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2015 16 Nephropathy - Pipeline by Ischemix, H1 2015 17 Nephropathy - Pipeline by Promedior, Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Nephropathy Therapeutics - Recent Pipeline Updates, H1 2015 44 Nephropathy - Dormant Projects, H1 2015 53 Nephropathy - Discontinued Products, H1 2015 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.